Dr. Gottlieb has called for making it easier to market generic versions of complex drugs like Advair to reduce prices, but he also received close to $90, 000 in fees in 2016 and the first two months of this year as a Glaxo consultant, according to financial disclosures. Some say a yearlong recusal would not suffice. " The question is going to be, are you going to have to recuse yourself from all the decisions that are going to have an impact on that company?" said Dr. Wood, who is now an associate professor at George Washington University. 